Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Trial of Intermittent Androgen Deprivation Therapy Alone or Combined With [177Lu]Lu-PSMA-617, With or Without Abiraterone and Prednisone, in Patients With Low-Volume Metastatic Hormone-Sensitive Prostate Cancer

NCT07650240 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07650240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07650240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Trial of Intermittent Androgen Deprivation Therapy Alone or Combined With [177Lu]Lu-PSMA-617, With or Without Abiraterone and Prednisone, in Patients With Low-Volume Metastatic Hormone-Sensitive Prostate Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
August 4, 2026
Completion date
December 30, 2030
Enrollment
202 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate, advanced prostate adenocarcinoma, advanced prostate cancer, castration-sensitive prostate cancer, localized prostate carcinoma, metastatic hormone-sensitive prostate cancer (mhspc), metastatic prostate adenocarcinoma, metastatic prostate cancer, prostate adenocarcinoma, prostate cancer, recurrent prostate adenocarcinoma, stage ivb prostate cancer ajcc v8